The pharma giant signed a contract with the Defense Advanced Research Projects Agency and the Biomedical Advanced Research and Development Authority to launch an early clinical trial testing the antibodies’ effectiveness. It also sanctioned two immune proteins from Vanderbilt.
If trials are successful, the antibodies could become an alternative to a COVID-19 vaccine in certain cases.
More articles on pharmacy:
Drug wholesale, net prices increasing at slower rate, study says
U of Utah terminates faculty appointment of researcher involved in retracted Lancet study
FDA announces pilot program to curb illegal opioid sales
